Does the FDA have regulatory authority over adult autologous stem cell therapies? 21 CFR 1271 and the emperor's new clothes

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Freeman, Michael ^a   Fuerst, Mitchell ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; DRUG MANUFACTURE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; HEALTH CARE POLICY; HUMAN; INFORMED CONSENT; MEDICAL CARE; MEDICAL PRACTICE; NOTE; PATIENT SAFETY; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; ANIMAL; STEM CELL RESEARCH;

ANIMALS; HUMANS; STEM CELL RESEARCH;

EID: 84858731018     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-60     Document Type: Note

References (18)

1. Ichim TE, Riordan NH, Stroncek DF. The King is Dead, Long Live the King: Entering A New Era of Stem Cell Research and Clinical Development. J Transl Med 2011, 9(1):218. 10.1186/1479-5876-9-218, 3275507, 22185188.
2. Title 21-Food and Drugs Code of federal regulations. 2005, 8:716-719. Title 21-Food and Drugs.
3. Food Drug and Cosmetic Act, in 21 CFR 1270.1(c). United States 2006,
4. USFDA Proposed Approach to Regulation of Cellular and Tissue Based Products. Federal Register 1997, 62. USFDA.
5. Anitua E, et al. Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities. J Biomed Mater Res A 2006, 77(2):285-93.
6. Sanchez M, et al. Plasma rich in growth factors to treat an articular cartilage avulsion: a case report. Med Sci Sports Exerc 2003, 35(10):1648-52. 10.1249/01.MSS.0000089344.44434.50, 14523300.
7. Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med 2010, 83(1):1-9. 2844688, 20351977.
8. Alhadlaq A, Mao JJ. Mesenchymal stem cells: isolation and therapeutics. Stem Cells Dev 2004, 13(4):436-48. 10.1089/scd.2004.13.436, 15345137.
9. USFDA Application of Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products. Federal Register 1993, 58. USFDA.
10. USFDA Applications for Products Comprised of Living Autologous Cells Manipulated Ex Vivo for Structural Repair or Reconstitution. Federal Register 1996, 61. USFDA.
11. USFDA Establishment Registration and Listing for Manufacturers of Human Cellular and Tissue-Based Products, CBER, Editor 1988, USFDA.
12. Malarkey MR. Sciences 2008, Director of Compliance and Biologics Quality, U.S. Food and Drug Administration.
13. Riska EB, Michelsson JE. Treatment of para-articular ossification after total hip replacement by excision and use of free fat transplants. Acta Orthop Scand 1979, 50(6 Pt 2):751-4.
14. Group, F.T.R. 2011 12/20/2011] Letter concerning the use of an adipose SVF fraction in orthopedic conditions Group, F.T.R. 2011 12/20/2011]., http://www.docstoc.com/docs/102968214/FDA-Claims-Adipose-SVF-is-a-Drug
15. Ricardo Rodriguez, M.DL 2012, FDA: Stem Cells from Your Own Fat are a Drug, Ricardo Rodriguez, M.DL., http://www.cosmeticsurg.net/blog/2012/01/11/fda-stem-cells-from-your-own-fat-are-a-drug/
16. FDA, U 21 CFR 1271.3 - How does FDA define important terms in this part? 2011, Code of Federal Regulations - Title 21: Food and Drugs, [cited 2012 2/1/12]; Available from: http://cfr.vlex.com/vid/1271-3-does-fda-define-important-terms-19717097, FDA, U.
17. Schafer R, et al. Functional investigations on human mesenchymal stem cells exposed to magnetic fields and labeled with clinically approved iron nanoparticles. BMC Cell Biol 2010, 11(1):22. 10.1186/1471-2121-11-22, 2871263, 20370915.
18. US vs. Regenerative Sciences 2012, US District Court for the District of Columbia.